<DOC>
	<DOCNO>NCT00005583</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether radiation therapy chemotherapy effective radiation therapy alone treat high-risk endometrial cancer . PURPOSE : This randomized phase III trial study radiation therapy chemotherapy see well work compare radiation therapy alone treat patient high-risk endometrial cancer .</brief_summary>
	<brief_title>Radiation Therapy With Without Chemotherapy Treating Patients With High-Risk Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare relapse-free survival patient high-risk endometrial carcinoma treat adjuvant set either radiotherapy alone radiotherapy chemotherapy give sequentially . - Compare overall survival patient population treat 2 adjuvant regimen . - Evaluate addition chemotherapy standard adjuvant radiotherapy , term toxicity , patient . - Study whether pattern relapse patient influenced addition chemotherapy adjuvant radiotherapy . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord center histologic type ( serous papillary clear cell v type ) . Patients randomize 1 2 treatment arm . All patient undergo hysterectomy bilateral salpingooophorectomy extirpation macroscopic suspicious lymph node . - Arm I : Within 7 week surgery , patient begin radiotherapy . - Arm II : Patients receive radiotherapy follow preceded chemotherapy* . Patients receive cisplatin IV 60 minute doxorubicin epirubicin IV 10-20 minute day 1 . Treament repeat every 21 day 4 course . NOTE : *If radiotherapy precede chemotherapy , radiotherapy begin within 4 week chemotherapy . Patients follow 3 6 month every 6 month 5 year . PROJECTED ACCRUAL : A total 400 patient ( 200 per treatment arm ) accrue study within 5 year .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm endometrial cancer 1 follow type : Clear cell carcinoma Serous papillary carcinoma Undifferentiated ( anaplastic ) carcinoma Poorly differentiate ( FIGO grade 3 ) adenocarcinoma infiltration half myometrial thickness No small cell carcinoma neuroendocrine differentiation Primary FIGO surgical stage I occult stage II No spread disease outside uterine corpus except pelvic lymph nod No spread disease paraaortic lymph node Positive peritoneal washing allow No preoperative macroscopic tumor involvement cervix Microscopic tumor involvement cervix histopathological evaluation operative uterine specimen allow PATIENT CHARACTERISTICS : Age : Any age Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Adequate bone marrow function WBC least 3,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Adequate hepatic function Renal : Adequate renal function Creatinine great 1.4 mg/dL Pulmonary : Adequate pulmonary function Other : Not pregnant nursing Fit receive combination chemotherapy No malignancy except basal cell squamous cell skin cancer No uncontrolled potentially active site infection ( e.g. , fistula abscess ) No concurrent condition would produce substantial increase risk complication radiotherapy No concurrent condition would interfere adequate followup PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No prior preoperative irradiation Surgery : No prior extensive abdominal surgery</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>stage I endometrial carcinoma</keyword>
	<keyword>stage II endometrial carcinoma</keyword>
	<keyword>endometrial adenocarcinoma</keyword>
	<keyword>endometrial papillary serous carcinoma</keyword>
	<keyword>endometrial clear cell carcinoma</keyword>
</DOC>